{"url_path":"/sec/armp/8-k/2026-07-13/item-7-01","section_key":"item-7-01","section_title":"Item 7.01 **","topic":"sec","document":{"doc_type":"8-K","doc_date":"2026-07-13","source_url":"https://www.sec.gov/Archives/edgar/data/921114/0001104659-26-082850-index.html","accession_number":"0001104659-26-082850","cik":"0000921114","ticker":"ARMP","issuer_name":"Armata Pharmaceuticals, Inc.","edgar_url":"https://www.sec.gov/Archives/edgar/data/921114/0001104659-26-082850-index.html","primary_entity_key":"0000921114","primary_entity_name":"Armata Pharmaceuticals, Inc."},"word_count":169,"has_tables":true,"body_markdown":"**Item 7.01**\n**Regulation FD Disclosure.**\n\n \n\nOn July 13, 2026, Armata Pharmaceuticals, Inc.\n(the “Company”) issued a press release announcing that it has received agreement from the U.S. Food and Drug Administration\n(the “FDA”) on an Agreed Initial Pediatric Study Plan (“Agreed iPSP”), which establishes the agreed regulatory\nframework for the future evaluation of AP-SA02 for the adjunct treatment of complicated *Staphylococcus aureus* bacteremia (“SAB”)\nin pediatric patients. The full text of the press release issued in connection with this announcement is furnished as Exhibit 99.1 to\nthis Current Report on Form 8-K.\n\n \n\nThe information in this Item 7.01 and the attached Exhibit 99.1 is being furnished and shall not be deemed “filed” for the\npurposes of Section 18 of the Securities Exchange Act of 1934, as amended, or otherwise subject to the liabilities of that Section. The\ninformation in this Item 7.01 and the attached Exhibit 99.1 shall not be incorporated by reference into any registration statement or\nother document pursuant to the Securities Act of 1933, as amended."}